A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1
Recruiting
- Conditions
- CancerSquamous Cell CarcinomaMerkel Cell CarcinomaNeoplasmsTriple Negative Breast CancerOvarian CancerBladder CancerGastric CancerUrothelial CarcinomaMetastatic Cancer
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Ocellaris Pharma, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT04260802
- Locations
- 🇨🇦
Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Ottawa Hospital Cancer Centre (OHRI), Ottawa, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath